RESEARCH ARTICLE

Trends in HIV care cascade engagement among diagnosed people living with HIV in Ontario, Canada: A retrospective, population-based cohort study

James Wilton1‡, Juan Liu2‡, Ashleigh Sullivan3, Beth Rachlis1,4,5, Alex Marchand-Austin2, Madison Giles1, Lucia Light1, Claudia Rank3, Ann N. Burchell6,7,8, Sandra Gardner9,10, Doug Sider2, Mark Gilbert11,12, Abigail E. Kroch1,4*, Ontario HIV Epidemiology and Surveillance Initiative¶

1 Data and Applied Science Impact, Ontario HIV Treatment Network, Toronto, Canada, 2 Public Health Ontario, Toronto, Canada, 3 Public Health Agency of Canada, Ottawa, Canada, 4 Division of Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada, 5 Dignitas International, Toronto, Ontario, Canada, 6 Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, Canada, 7 Department of Family and Community Medicine, St. Michael’s Hospital, Toronto, Canada, 8 Department of Family and Community Medicine and Dalla Lana School of Public Health, University of Toronto, Toronto, Canada, 9 Baycrest Health Sciences, Toronto, Canada, 10 Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada, 11 Clinical Prevention Services, British Columbia Centre for Disease Control, Vancouver, Canada, 12 School of Population and Public Health, University of British Columbia, Vancouver, Canada

‡ JW and JL are joint first authors on this work.
¶ Membership of the Ontario HIV Epidemiology and Surveillance Initiative is provided in the Acknowledgements.
*
akroch@ohtn.on.ca

Abstract

Background

The HIV cascade is an important framework for assessing systems of care, but population-based assessment is lacking for most jurisdictions worldwide. We measured cascade indicators over time in a population-based cohort of diagnosed people living with HIV (PLWH) in Ontario, Canada.

Methods

We created a retrospective cohort of diagnosed PLWH using a centralized laboratory database with HIV diagnostic and viral load (VL) test records linked at the individual-level. Individuals enter the cohort with record of a nominal HIV-positive diagnostic test or VL test, and remain unless administratively lost to follow-up (LTFU, >2 consecutive years with no VL test and no VL test in later years). We calculated the annual percent of diagnosed PLWH (cohort individuals not LTFU) between 2000 and 2015 who were in care (≥1 VL test), on ART (as documented on VL test requisition) or virally suppressed (<200 copies/ml). We also calculated time from diagnosis to linkage to care and viral suppression among individuals newly diagnosed with HIV. Analyses were stratified by sex and age. Upper/lower bounds were calculated using alternative indicator definitions.
Results
The number of diagnosed PLWH increased from 8,859 (8,859–11,389) in 2000 to 16,110 (16,110–17,423) in 2015. Over this 16-year period, the percent of diagnosed PLWH who were: in care increased from 81% (63–81%) to 87% (81–87%), on ART increased from 55% (34–60%) to 81% (70–82%) and virally suppressed increased from 41% (23–46%) to 80% (67–81%). Between 2000 and 2014, the percent of newly diagnosed individuals who linked to care within three months of diagnosis or achieved viral suppression within six months of diagnosis increased from 67% to 82% and from 22% to 42%, respectively. Estimates were generally lower for females and younger individuals.

Discussion
HIV cascade indicators among diagnosed PLWH in Ontario improved between 2000 and 2015, but gaps still remain—particularly for younger individuals.

Introduction
In recent years, the HIV cascade has become an important framework for monitoring HIV care, identifying gaps and informing/evaluating appropriate interventions [1]. The HIV cascade refers to the components of HIV diagnosis and care that people living with HIV (PLWH) progress through to achieve and maintain a suppressed viral load (VL). These components include testing and diagnosis, linkage to and retention in medical care, and initiation of and adherence to antiretroviral treatment (ART) [2]. With recent evidence supporting earlier initiation of ART to improve individual health and prevent HIV transmission to a partner [3,4], as well as a growing interest in the use of ART to reduce HIV incidence at a population-level [5–7], HIV policy and programming has increasingly focused on measuring and improving engagement in the HIV cascade. Indeed, the cascade framework has become the basis of several regional, national and international HIV policies, including the recent UNAIDS 90-90-90 strategy which calls for 90% of people living with HIV (PLWH) to be diagnosed, 90% of diagnosed PLWH to be on ART, and 90% of PLWH on ART to be virally suppressed by 2020 [8].

Although relatively simple in concept, there are several methodological challenges to measuring the cascade in ways that are representative of and comparable across jurisdictions [9–14]. These challenges include the lack of standardized cascade metrics, as well as limitations inherent to the varied data sources available. To understand and overcome these challenges, Medland and co-authors published a systematic review of cascade studies in 2015 [15]. In addition to proposing standardized metrics, the authors identified only six jurisdictions worldwide with optimal cascades; that is, “broad” cascades (i.e. include data on the number of infected/diagnosed PLWH through to the number suppressed) [10] constructed from population-based data sources (i.e. individual-level data collected across an entire population). These jurisdictions included New York City [16], King County in Washington State [17], British Columbia (BC) [18], Denmark [19], Georgia [20] and a study of 18 states and the District of Columbia representing approximately 40% of diagnosed PLWH in the US [21]. Further, only one of these studies used a cohort-based approach, which is optimal for longitudinal cascade measurement [10]. Instead, most published cascade analyses use clinical cohorts of PLWH who have already entered care and thus cannot be used to construct “broad” cascades [22–25], or extrapolate from non-population-based data sources and thus lack individual-level linkage.
from diagnosis to suppression (i.e. conduct analyses at the aggregate level) [26–30]. The lack of optimal data sources/approaches [10,15] means that accurate and comprehensive knowledge across the full continuum of care may be lacking for most jurisdictions worldwide.

Analysis of the HIV cascade in Ontario—Canada’s largest province (population 14.0 million) [31]—has been limited. Ontario has experienced the greatest burden of HIV in the country and about 40% of the ~80,000 HIV cases between 1985 and 2016 in Canada were diagnosed in Ontario [32,33]. In 2016, the HIV diagnosis rate per 100,000 people in Ontario (6.3) was comparable to the national average (6.4) [33]. Despite an overall decrease in the rate of HIV diagnoses and mortality among PLWH over time [34,35], approximately 800 to 900 HIV infections continue to be diagnosed in Ontario each year [34] and mortality remains higher for PLWH than the general population [35]. These data suggest there is room for improvement in HIV prevention and treatment in Ontario, and the provincial HIV/AIDS strategy launched in 2018 prioritizes cascade measurement to guide and evaluate HIV policy and programming [36]. However, analyses of cascade components to date have mostly been limited to a clinical cohort following approximately 25–30% of PLWH actively receiving medical care in the province [37], as well as a population-based administrative cohort of PLWH who have entered care that lacks information on viral suppression—a key component of the cascade [35,38,39]. While both of these data sources have important strengths, they are not optimal for assessing the full continuum of care at the level of Ontario’s population.

To improve our understanding of Ontario’s cascade, we created a population-based cohort of diagnosed PLWH (referred to as the Ontario HIV Laboratory Cohort) using a centralized laboratory database with HIV diagnostic and viral load (VL) test records linked at the individual-level. In this paper, we assess cascade indicators over time and by sex and age among diagnosed PLWH in the Ontario HIV Laboratory Cohort. Our primary objectives were to measure trends in the annual proportion of diagnosed PLWH who were in care, on ART and virally suppressed. We also aimed to measure time from diagnosis to linkage to care and viral suppression among individuals who were newly diagnosed with HIV in Ontario.

**Methods**

**Setting**

Ontario is Canada’s most populous province [31]. Access to medically necessary services (including HIV medical care visits and laboratory testing) are free for those living in Ontario who are eligible (e.g. Canadian citizens, permanent residents) and registered with the province’s health care plan. However, in Ontario, there is no universal coverage of ART medications. Individuals can obtain coverage through private health insurance or may be eligible for government-sponsored programs [40]. However, private and public coverage is not always full and often requires some form of payment to cover deductibles/co-payments [41].

**Data sources**

Public Health Ontario Laboratory HIV datamart and Ontario HIV Laboratory Cohort. The Ontario HIV Laboratory Cohort is a retrospective, population-based cohort of diagnosed PLWH in Ontario, Canada. This cohort was created using the HIV datamart at Public Health Ontario Laboratory (PHOL). The HIV datamart and creation of the Ontario HIV Laboratory Cohort are described below.

The HIV datamart was developed using HIV clinical laboratory databases housed at PHOL. All HIV diagnostic and VL testing conducted by health care providers in Ontario is done by PHOL. Centralized databases contain information on test results and information documented by the ordering provider on test requisition/surveillance forms. The diagnostic test
requisition collects information on sex, age and HIV exposure category while the VL test requisition collects information on sex, age, ART medications and most recent CD4 count. A follow-up surveillance form (the Laboratory Enhancement Program, LEP, questionnaire) is sent to an ordering provider if a diagnostic test result is HIV-positive in order to collect further information on the diagnosed individual. This includes information collected on the diagnostic test requisition (e.g. exposure category), as well as information not collected on the requisition (e.g. race/ethnicity and country of birth). The LEP form was introduced in 1999 and race/ethnicity and country of birth were added to the questionnaire in 2009. The previously separate diagnostic and VL databases were recently integrated by Public Health Ontario and records linked at the individual-level to create a single population-based data source (hereafter referred to as the “HIV datamart”). Of note, the majority of HIV diagnostic testing in Ontario is conducted nominally (i.e. using the name of the person tested), although non-nominal forms of testing (i.e. using anonymous or coded identifiers) are permitted. VL testing in Ontario is conducted as part of routine care for people already diagnosed with HIV. While anonymous VL testing has been permitted as of July 1st 2015, all VL tests in the database were nominal as of the end of 2015.

We used the HIV datamart to create a cohort of diagnosed PLWH in Ontario for retrospective measurement of cascade indicators. Individuals in the datamart enter the cohort with first record of a nominal HIV-positive diagnostic test or VL test. Non-nominal HIV-positive diagnoses are excluded due to insufficient identifying information to allow linkage to other diagnostic/VL tests (thus precluding the ability to identify possible duplication in the nominal data, as well as measure subsequent engagement in care). However, while non-nominal tests are excluded, individuals diagnosed non-nominally enter the cohort when they link to care and receive a nominal VL test. As such, individuals with a VL test only (no linked HIV-positive diagnostic test) are included in the cohort to capture individuals diagnosed non-nominally, as well as previously diagnosed individuals migrating into the province. All individuals who enter the cohort are defined as a person with diagnosed HIV.

Individuals in the cohort remain unless administratively lost-to-follow up (LTFU), defined as having had no VL test for >2 consecutive years and no VL test in later years. The LTFU rule was applied to indirectly censor for death and migration out of the province (out-migration), as this information was lacking from our laboratory databases. Importantly, participants assessed as LTFU are not permanently censored and, as time progresses, these individuals can re-enter the cohort with subsequent record of a VL test. We selected 2 years for the LTFU criteria given that this would capture most individuals experiencing a known gap in care in our cohort (i.e. no VL test in ≥1 year but record of a VL test in a later year). The duration of this LTFU criteria is similar to what has been used elsewhere [18,37]. We define cohort individuals who are not LTFU as diagnosed people living with HIV (PLWH) in Ontario.

Newly diagnosed sample. We also used the datamart to create a subset of individuals who were newly diagnosed with HIV in Ontario (i.e. were not initially diagnosed elsewhere and then moved to Ontario) in order to measure longitudinal cascade indicators (i.e. time from diagnosis to linkage to care and viral suppression). This newly diagnosed subset includes individuals with record of a nominal HIV-positive diagnostic test and excludes individuals with 1) a VL test only (i.e. no linked HIV-positive diagnostic test—as this precludes measurement of time from HIV diagnosis) and 2) evidence of having received an HIV-positive diagnosis prior to their first nominal HIV-positive diagnostic test record in Ontario (i.e. record of a CD4 or detectable VL test before diagnosis, or a first VL test after diagnosis that was suppressed).
## Indicators and definitions

Our cascade indicators are summarized in Table 1. We selected and defined indicators based on available data, a review of the literature, and expert opinion—with most being similar to those recommended by Medland et al in a recent systematic review [15].

| Indicator | Definition (numerator) | Denominator used for calculating percent of individuals per calendar year | 2015 cohort estimates |
|-----------|------------------------|------------------------------------------------------------------------|----------------------|
| **Diagnosed PLWH** | | | |
| Main | Confirmed nominal HIV-positive diagnostic test and/or $\geq$ 1 VL test, and not administratively lost to follow-up after 2 years | — | 16,110 |
| Upper | Confirmed HIV-positive diagnostic test (nominal or non-nominal) and/or $\geq$ 1 VL test, and not administratively lost to follow-up after 3 years | — | 17,423 |
| **In care** | | | |
| Main | $\geq$ 1 VL test in given year | Diagnosed PLWH (Main) | 87.3% |
| Lower | $\geq$ 1 VL test in given year | Diagnosed PLWH (Upper) | 80.7% |
| **On ART** | | | |
| Main | Documented on ART, or ART status not documented and suppressed, on last VL test in a given year | Diagnosed PLWH (Main) | 81.1% |
| Upper | Documented on ART, or ART status not documented and suppressed, on any VL test in a given year | Diagnosed PLWH (Main) | 82.0% |
| Lower | Documented on ART, or ART status not documented and suppressed, on all VL tests in a given year | Diagnosed PLWH (Upper) | 69.9% |
| **Virally suppressed** | | | |
| Main | VL $< 200$ copies/mL, on last VL test in a given year | Diagnosed PLWH (Main) | 79.5% |
| Upper | VL $< 200$ copies/mL, on any VL test in a given year | Diagnosed PLWH (Main) | 80.8% |
| Lower | VL $< 200$ copies/mL, on all VL tests in a given year | Diagnosed PLWH (Upper) | 67.4% |
| **Virally suppressed (among those on ART)** | | | |
| Main | VL $< 200$ copies/mL, and known on ART or ART status not documented, on last VL test in a given year | Documented on ART on last VL, or ART status not documented, on last VL test in a given year | 94.4% |
| Upper | VL $< 200$ copies/mL, and known on ART or ART status not documented, on any VL test in a given year | Documented on ART, or ART status not documented, on any VL test in a given year | 95.1% |
| Lower | VL $< 200$ copies/mL, and known on ART or ART status not documented, on all VL tests in a given year | Documented on ART, or ART status not documented, on all VL tests in a given year | 90.9% |
| **Newly diagnosed** | | | |
| Main | Confirmed nominal HIV-positive diagnostic test and no evidence of diagnosis prior to nominal HIV-positive diagnostic test | — | 473 (2014 estimate) |
| **Time to linkage to care** | | | |
| Main | First VL test $\leq$ 3 months after diagnosis | Newly diagnosed (Main) | 81.8% (2014 estimate) |
| **Time to suppression** | | | |
| Main | First suppressed VL ($< 200$ copies/ml) $\leq$ 6 months after diagnosis | Newly diagnosed (Main) | 41.6% (2014 estimate) |

ART status documented by providers on VL test requisitions and missing from 17–20% of requisitions each year. Assumptions for requisitions with missing ART data differ by indicator. Bold text highlights differences between main and upper/lower definitions. 2015 estimates not shown for newly diagnosed indicators to avoid truncation bias.

* Conditional estimates were also calculated for these indicators using the number ‘in care’ in the denominator. VL = viral load. ART = antiretroviral treatment. PLWH = people living with HIV.

[https://doi.org/10.1371/journal.pone.0210096.t001](https://doi.org/10.1371/journal.pone.0210096.t001)
contrast to Medland et al [15], we used the term “in care” instead of “retention in care”, as we felt this is more reflective of what the indicator is measuring (i.e. while our dataset is longitudinal, the measure of ≥1 VL test in a given year is cross-sectional in nature and doesn’t track an individual’s retention longitudinally). In addition to the elements recommended by Medland et al, we also measured time from diagnosis to viral suppression, as done by others [42,43]. While linkage to care is defined as the percent of individuals who linked to care within 3 months of diagnosis [15], there is no recommended threshold for time from diagnosis to suppression. In the presentation of our results, we focus on the percent suppressed within 6 months. Of note, the national HIV/AIDS strategy in the United States shortened the threshold for their linkage to care indicator from 3 months to 1 month in 2015 [44]. Therefore, we also include the proportion linked to care within 1 month of diagnosis in respective figures.

Medland et al recommend that cascade indicators be presented as both the percent of all PLWH in a jurisdiction (diagnosed and undiagnosed) as well as all diagnosed PLWH [15]. In our analysis, we only present cascade indicators as the percent of diagnosed PLWH, as the total HIV-infected population in the province was not measurable in our cohort and modeling estimates over this time period are currently under development in Ontario. To quantify attrition at each cascade step and facilitate comparison to the third UNAIDS 90-90-90 estimate, we also calculated conditional estimates of those “on ART” and “virally suppressed” by limiting the denominator to individuals who had already achieved the previous indicator(s) (i.e. were already “in care” or “on ART”).

For each cascade indicator, we created a “main” definition based on the most commonly used and recommended approach. In keeping with recommendations to present a range of plausible estimates (as opposed to what may be artificially precise single estimates) [14], we also calculated “upper” and “lower” bounds. These upper/lower bounds were calculated using alternative assumptions/definitions for each indicator, where possible. Alternative assumptions/definitions were employed to improve our ability to compare across studies (as there is no consistent standard for cascade metrics across the literature) and to accommodate possible biases due to inherent aspects unique to our data source. Of note, for our alternative (“upper”) definition of the number of diagnosed PLWH (cohort individuals not LTFU), we altered our eligibility criteria to include non-nominal HIV-positive diagnoses and extended the LTFU criteria from two to three years. We used this “upper” diagnosed PLWH definition in the denominator to calculate “lower” estimates of the percent “in care”, “on ART” and “virally suppressed”. For our main definition of “virally suppressed”, we used the most recent VL test in a given year, which is the approach most commonly used [16,17,21] and recommended [45] by others, but is not specified by Medland et al [15].

Our “on ART” indicator was based on documentation of specific antiretroviral medications by the ordering provider on VL test requisition forms. This information was missing for approximately 17–20% of requisitions each year. To address these missing data in our analysis, we made conservative assumptions regarding ART status (i.e. on or off ART) for requisitions with missing information. In order to calculate conservative estimates, our assumptions differed depending on whether “on ART” was used in the numerator or denominator of the indicator calculated. When “on ART” was in the numerator (to calculate the percent of diagnosed PLWH who were on ART), requisitions missing information were only assumed to be on ART if the VL was suppressed. When “on ART” was in the denominator (to calculate the percent of PLWH on ART who were suppressed), all requisitions with missing ART information were assumed to be on ART.
Analysis

We restricted our analyses to the period from January 1, 2000 to December 31, 2015. Although VL testing was implemented in 1996, it took several years to become a routine part of HIV care and thus serve as an accurate proxy for linkage to and engagement in care [46].

We used data from the Ontario HIV Laboratory Cohort to measure trends in the annual percent of diagnosed PLWH who were in care, on ART and virally suppressed, as well as conditional estimates for the on ART and virally suppressed indicators. Cohort participants were included in the analyses of annual cascade measures until administratively LTFU. Individuals were assumed to be off ART and unsuppressed if they did not have a VL test in a given year. Individuals who re-entered the cohort after being LTFU were counted as being a diagnosed PLWH who did not meet any of the cascade indicator definitions for the years in which they were LTFU.

We used data from the newly diagnosed subset to measure trends in the annual percent of newly diagnosed individuals who linked to care within three months of diagnosis (i.e. linkage to care) and achieved viral suppression within six months of diagnosis. Among those with record of a VL test or suppressed VL, we also calculated the median number of days from diagnosis-to-care and diagnosis-to-suppression, respectively. To minimize truncation bias, we excluded individuals newly diagnosed in 2015 from the diagnosis-to-care analyses and those diagnosed in 2014 and 2015 from the diagnosis-to-suppression analyses, given that individuals diagnosed in these years may not have had sufficient time to reach these endpoints by end of 2015.

We assessed cascade indicators by sex and age, both of which are collected on the diagnostic and VL test requisition forms and missing for less than 1% of the cohort. We did not explore indicators by race/ethnicity or HIV exposure category as this information was missing for approximately half of participants or more. This missing information was due to a combination of factors, including providers not filling out diagnostic requisition forms and race/ethnicity not being collected on the LEP prior to 2009. In addition, race/ethnicity and HIV exposure category are not collected on VL test requisition forms and are therefore missing for participants with no linked HIV diagnostic test (approximately 25% of participants).

All analyses were descriptive and no formal statistical testing across time or populations was conducted. We considered this reasonable as our data is population-based (not a random sample) [47] and the large sample size would mean even small differences are statistically significant [48].

Ethical approval

This applied research study was approved by the Ethics Review Board at Public Health Ontario.

Results

Cohort creation and follow-up

As of 2015, there were a cumulative total of 40,372 confirmed HIV-positive diagnostic test records (1985–2015) and 23,851 unique individuals with a record of ≥1 VL test (1996–2015) in the HIV datamart (Fig 1). Of the HIV-positive diagnostic tests, 18,683 (46.3%) were conducted non-nominally and excluded from the cohort. Of note, the percent of diagnostic tests that were non-nominal decreased from 48.9% in 2000 to 15.0% in 2015 (S1 Table).

Overall, 29,587 unique individuals with a nominal HIV-positive diagnostic test and/or ≥1 VL test were included in the cohort. As of the end of 2015, these individuals had been followed
for a cumulative total of 229,302 person-years and 552,855 VL tests. Between 2000 and 2015, the number of diagnosed PLWH (cohort individuals not LTFU) increased from 8,859 (upper bound: 11,389) to 16,110 (upper bound: 17,423) (Fig 2A).

Cohort sociodemographic profile

In 2015, the majority of the 16,110 diagnosed PLWH in the cohort were male (79.6%) or 45 years of age or older (62.6%) (Table 2). The percent of diagnosed PLWH who were 45 years of age or older doubled from 29.1% in 2000 to 62.6% in 2015, while the percent who were female increased from 15.0% in 2000 to 20.0% in 2008 and has since remained relatively stable (Tables A and B in S2 Table).

Date of diagnosis, race/ethnicity and HIV exposure category were missing for a large proportion of participants (Table 2). Where this information was known, the majority of individuals in 2015 were diagnosed between 2006 and 2015 (54.9%), the most common race/ethnicity was White (51.4%) followed by Black (26.9%), and the most common HIV exposure category was men who have sex with men (46.4%) followed by heterosexual (18.5%).

Cascade indicators

Indicator estimates for the most recent years of analysis (2014/2015) are summarized in Table 1. Trends over time and breakdowns by sex and age are summarized below and in Figs 2–5. Data underlying all figures can be found in the Tables in S1 Supporting Information.

Main indicators among diagnosed PLWH. The percent of diagnosed PLWH who were in care, on ART and virally suppressed all increased over time. Between 2000 and 2015, the percent who were in care increased from 81.3% (lower bound: 63.2%) to 87.3% (lower bound:
80.7%) (Fig 2B), the percent who were on ART increased from 55.1% (lower and upper bounds: 34.3%-60.2%) to 81.1% (69.9%-82.0%) (Fig 2C) and the percent who were virally suppressed increased from 40.7% (23.3%-46.1%) to 79.5% (67.4%-80.8%) (Fig 2D).

**Conditional indicators among diagnosed PLWH.** Between 2000 and 2015, the percent of PLWH in care who were on ART increased from 67.7% (54.3%-74.1%) to 92.8% (86.6%-93.9%) (Fig 3A) and who were suppressed increased from 50.1% (36.9%-56.7%) to 91.1% (83.5%-92.5%) (Fig 3B). Over the same time period, the percent of PLWH on ART who were suppressed increased from 63.2% (54.7%-66.2%) to 94.4% (90.9%-95.1%) (Fig 3C).

**Longitudinal indicators among newly diagnosed individuals.** Between 1996 and 2015, 19,386 individuals were diagnosed nominally and eligible for inclusion in the newly diagnosed subset (Figure A in S2 Supporting Information shows flow diagram). Of these, 5,976 (30.8%) had evidence of being previously diagnosed and were excluded. A total of 8,173 were newly diagnosed from 2000 onwards and included in our analyses of time from diagnosis to care and viral suppression. Between 2000 and 2015, the median annual number of newly diagnosed individuals was 529 (range: 368–599) (Table A in S2 Supporting Information).

Time from diagnosis to linkage to care and viral suppression both improved over time (Fig 4). The percent of newly diagnosed individuals who linked to care within 3 months of diagnosis increased from 67.4% in 2000 to 81.8% in 2014 (Fig 4A). The percent who achieved
Table 2. Sociodemographic characteristics of diagnosed PLWH in the Ontario HIV Laboratory Cohort, 2015 (N = 16,110).

| Characteristic                              | Diagnosed PLWH |
|---------------------------------------------|----------------|
|                                            | n   | %     |
| **Sex (where known)**                       |     |       |
| Female                                      | 3,257 | 20.4% |
| Male                                        | 12,724 | 79.6% |
| **Age (where known)**                       |     |       |
| <25                                         | 469 | 2.9% |
| 25–34                                       | 2,009 | 12.5% |
| 35–44                                       | 3,529 | 22.0% |
| 45–54                                       | 5,737 | 35.7% |
| 55+                                         | 4,329 | 26.9% |
| **Period of HIV diagnosis (where known)**   |     |       |
| Prior to 1996                               | 1,548 | 13.7% |
| 1996–2000                                   | 1,325 | 11.7% |
| 2001–2005                                   | 2,230 | 19.7% |
| 2006–2010                                   | 2,916 | 25.7% |
| 2011–2015                                   | 3,306 | 29.2% |
| **Race/ethnicity (where known)**            |     |       |
| White                                       | 1,367 | 51.4% |
| Black                                       | 714 | 26.9% |
| Latin American                              | 163 | 6.1% |
| East/Southeast Asian                        | 145 | 5.5% |
| South Asian                                 | 108 | 4.1% |
| Indigenous                                  | 75 | 2.8% |
| Arab/West Asian                             | 46 | 1.7% |
| Other/mixed                                 | 40 | 1.5% |
| **HIV exposure category (where known)**     |     |       |
| MSM                                         | 3,787 | 46.4% |
| PWID                                        | 881 | 10.8% |
| Heterosexual                                | 1,515 | 18.5% |
| HIV-endemic                                 | 1,334 | 16.3% |
| No identified risk factor(s)                | 737 | 4.6% |
| **Missing**                                 |     |       |
| Sex                                         | 129 | 0.8% |
| Age                                         | 37 | 0.2% |
| Period of diagnosis                         | 4,785 | 29.7% |
| Race/ethnicity                              | 13,452 | 84.5% |
| Exposure category                           | 7,941 | 49.3% |

Diagnosed PLWH are cohort participants not lost to follow-up. All characteristics mutually exclusive, except for MSM and PWID exposure categories.

*Reasons for missing data include 1) ordering providers not filling out requisition forms, 2) race/ethnicity only being collected from 2009 onwards, and 3) information on these characteristics only being collected on diagnostic forms and therefore missing for the 29.7% of participants in 2015 with a VL test only (no linked diagnostic test).

MSM = men who have sex with men. PWID = people who use injection drugs. PLWH = people living with HIV.

https://doi.org/10.1371/journal.pone.0210096.t002
viral suppression within 6 months of diagnosis was relatively stable at approximately 20% between 2000 and 2007, and then increased to 41.4% by 2013 (Fig 4C).

The percent of newly diagnosed individuals who did not have a record of a VL test or suppressed VL was relatively stable over time at approximately 10% and 15%, respectively. Among newly diagnosed individuals with a record of these endpoints, time from diagnosis-to-care and diagnosis-to-suppression decreased over time. The median (IQR) number of days from diagnosis-to-care peaked at 48 (31–74) in 2002 and then decreased to 24 (12–43) days in 2014 (Fig 4B). The median (IQR) number of days from diagnosis-to-suppression peaked at 614 (202–1,469) in 2005 and then decreased to 172 (112–285) days in 2013 (Fig 4D).

Cascade indicators by sex and age. Indicators related to viral suppression are shown by sex and age in Fig 5 (main estimates only). All other indicators are shown by sex and age in the Tables in S3 Supporting Information.

Cascade estimates among diagnosed PLWH were generally consistently higher for males compared to females, but these differences were relatively minor and rarely exceeded seven absolute percentage points. In 2015, 80.4% of diagnosed male PLWH were virally suppressed compared to 76.5% of females (Fig 5A). In contrast, the percent of newly diagnosed individuals who linked to care within 3 months of diagnosis was relatively similar by sex and not consistently higher for males or females (Fig 5B).
Differences by age were more noticeable, with indicator estimates generally consistently higher for older age groups. In 2015, the percent of diagnosed PLWH who were virally suppressed was 64.2%, 67.9%, 76.4%, 82.2%, and 85.9% among those aged <25, 25–34, 35–44, 45–54, and 55+, respectively (Fig 5C). Across the same age gradient, the percent of newly diagnosed individuals in 2012–2014 who were virally suppressed within 6 months of diagnosis was 38.3%, 38.3%, 37.8%, 45.4%, and 46.9%, respectively (Fig 3D).

**Discussion**

We observed improved engagement in the HIV cascade among diagnosed PLWH in Ontario, Canada between 2000 and 2015. Our study is one of few published efforts to have measured the cascade using a population-based data source with individual-level linkage from diagnosis to suppression [15], and to our knowledge only the second of these to use a cohort-based approach [15,18], despite such data sources/approaches being recommended as optimal for cascade measurement [10,15]. In our study, the “linked to care” and “in care” indicators were both relatively high across the 16-year study period and increased only slightly, while there were more dramatic increases in the “on ART”, “virally suppressed”, and time from diagnosis-to-suppression indicators. These trends are similar to those observed in other population-based HIV cascade studies [16,18]. Improvements in cascade indicators over time are likely
due to a combination of factors, such as better access to care and ART, availability of ART regimens that are more effective and easier to take, changes to ART guidelines recommending earlier initiation of treatment and opposing treatment interruptions, the success of care and treatment initiatives, and/or changes in the diagnosed population over time.

Our results fill an important gap in HIV cascade knowledge in Ontario and complement other related studies. The Ontario HIV Treatment Network Cohort Study (OCS) follows over 4000 PLWH actively receiving medical care from specialty HIV clinics across the province and includes approximately a quarter of all PLWH receiving care in Ontario [49,50]. Our results are similar to those observed in the OCS: a relatively stable percent in care, increases in ART use beginning in the mid-2000s and a relatively constant increase in the percent who are virally suppressed [37]. Another study team in Ontario has developed an administrative cohort of PLWH using population-based data on physician billing claims housed at the Institute of Clinical Evaluative Sciences (ICES). Between 2009–2012, the majority of individuals in this cohort accessed HIV-related care through family physicians (55%) followed by HIV specialists (36%), while the remainder received little-to-no usual care (9%) [38]. Our estimate of about 15% of diagnosed PLWH who were not in care is higher than the 9% reported through the ICES cohort, which is expected as our cohort includes those who never enter care after diagnosis.

Fig 5. Trends in viral suppression indicators by sex and age category (main estimates only), Ontario HIV Laboratory Cohort, 2000-2014/15. A) Percent of diagnosed PLWH who were virally suppressed by sex. B) Percent of newly diagnosed individuals who achieved viral suppression within 6 months of HIV diagnosis by sex. C) Percent of diagnosed PLWH who were virally suppressed by age category. D) Percent of newly diagnosed individuals who achieved viral suppression within 6 months of HIV diagnosis by age category. In Fig D, percents averaged over three years to reduce year-to-year variation due to small counts. In Fig 5B and 5D, individuals with no VL are included in the denominator.

https://doi.org/10.1371/journal.pone.0210096.g005
Despite high and improving cascade estimates, we still identified gaps where improvement is needed. In 2015, 13% of diagnosed PLWH were not in care, 7% were in care but not on ART and 6% were on ART but not virally suppressed. These gaps were larger if the lower bounds for these indicators were considered. In addition, 18% were not linked to care within three months of diagnosis and 59% did not achieve viral suppression within six months.

Cascade indicators were also generally lower for younger individuals, as observed in a clinical HIV cohort in Ontario (the OCS) [37,51] and other jurisdictions [16,30,52]. While our analyses did not adjust for time since diagnosis (many older individuals may have had more time to progress through the cascade stages), others in Ontario have reported that the association between older age and higher indicator estimates remains after adjustment for this potential confounder [37]. Further, we observed more timely viral suppression among individuals who were newly diagnosed with HIV at older ages, an analysis which inherently adjusts for time since diagnosis. Possible barriers to HIV care and treatment among youth include stigma, housing instability, transportation, mental health and substance use issues, difficulty accessing appropriate support services, and challenges in transitioning from pediatric to adult care [53–55].

In contrast to studies from the United States [16,30], but similar to an analysis from the Canadian province of BC [52], our indicator estimates among diagnosed PLWH were consistently slightly lower for females. Importantly, however, we did not explore cascade estimates by sub-populations of males and females, and other studies have demonstrated lower engagement in care among heterosexual males compared to men who have sex with men [16,37,51,52]. Interestingly, we did not observe a consistent difference by sex in our longitudinal indicators among newly diagnosed cases. This may be due to dissimilarities between prevalent and newly diagnosed cases, or due to bias introduced by excluding individuals with a VL test only from the newly diagnosed sample. The latter may be true as many of these excluded individuals were likely non-nominally diagnosed individuals, and non-nominal diagnoses in Ontario are more likely to be MSM (Table A in S3 Table) who, as already mentioned, are a population that tends to experience better engagement in the cascade.

Comparisons to estimates from other population-based cascades are challenged by the heterogeneity and limitations of data sources available across jurisdictions, as well as the varied approaches used to censor for out-migration and death. Cascade indicators calculated with greater uniformity/certainty may be more useful for comparing between studies, such as the percent of VL tests in a given year that are virally suppressed. Our 2010 estimate for the percent of VL tests that were suppressed (79%) was higher than the US 19-jurisdiction study (69% in 2010) [21] and New York City (~72% in 2010) [16] but similar to King County (79% in 2011) [17] and Denmark (80% in 2010) [19]. However, even these comparisons may be limited by the different VL thresholds used to define viral suppression. Regardless, a potentially more valid and informative use of cascade data is to focus on intra-jurisdiction comparisons, such as analyses by time, age, sex and other sociodemographic characteristics. Future analyses of our cohort will attempt to stratify cascade measures by region and Ontario’s priority populations (e.g. gay, bisexual and other men who have sex with men, including trans men; African, Caribbean and Black communities; Indigenous persons; people who use drugs; at-risk women, including trans women), where possible, in order to identify further opportunities for cascade improvement.

Perhaps the most relevant comparison is to the cascade in BC (given the similar cohort-based methodology and Canadian setting), but this is particularly challenged by the different measurement approaches. The more stringent approach used in BC means that the province is often referenced as having lower cascade estimates compared to others [15], a result that would seem at odds with the province’s universal access to ART and progressive HIV policies.
and programming. In sensitivity analyses—where authors of the BC study adopt indicator definitions more similar to ours and others—the percent of diagnosed PLWH who were suppressed in 2010 increased from 49% to 70% [18], putting it on the higher end of cascade estimates compared to other jurisdictions. These sensitivity analyses further highlight the challenge in comparing between studies and the importance of a standardized approach.

We altered our main indicator definitions in order to calculate upper/lower bounds and found estimates to be particularly sensitive to the more conservative definitions. Alternative definitions/assumptions were based on the range of definitions used in the literature and the nature of our data source. Use of our more conservative “on ART” and “virally suppressed” definitions in the numerator (in which individuals must be on ART or suppressed on all VL tests in a year vs. the most recent test) lowered estimates among diagnosed PLWH by 5–9% and 6–8% absolute percentage points, respectively. In addition, use of our alternative “Upper” diagnosed PLWH definition in the denominator (in which non-nominal HIV-positive diagnoses were included and the LTFU criteria extended to 3 years) decreased these estimates by a further 6–12% and 6–9%, respectively. While these differences are not insignificant, an alternative approach to measuring the number of diagnosed PLWH in New York City led to a 23% absolute change in the percent virally suppressed [56]. The use of these alternative definitions/assumptions demonstrates how indicator estimates can be impacted by both definitions and methodological assumptions, and the importance of presenting a range of plausible estimates instead of what is likely an artificially precise single estimate [14].

Measuring progress towards the UNAIDS 90-90-90 target is a priority for cascade analyses. According to our 2015 estimates, roughly 81% of diagnosed PLWH were on ART (2nd UNAIDS 90 target) and 94% of PLWH on ART were virally suppressed (3rd UNAIDS 90 target). Assuming the national Canadian estimate for the 1st UNAIDS 90 target (80%) [57] applies to Ontario, then approximately 61% of all PLWH in the province would have been virally suppressed in 2015, which is short of the UNAIDS target of 73% when all 90-90-90 targets are simultaneously met. Modeling efforts are underway to estimate the total number of PLWH in Ontario in order to better measure progress towards the UNAIDS 90-90-90 target.

The main strengths of our study were the adoption of methodological recommendations from several reviews and studies. These recommendations include the use of population-based data sources to maximize representativeness of our jurisdiction [10,15], individual-level linkage from diagnosis to suppression to ensure “denominator-denominator” and “numerator-denominator” linkage and to maximize the internal consistency of our outcomes [10], use of a cohort-based approach to facilitate analysis of trends over time and measures of delay (i.e. time to care and suppression) [10,11], use of standardized cascade elements and definitions to improve comparability to other jurisdictions [15], and use of alternative definitions/assumptions to create a range of plausible bounds around main estimates [14].

Our study had limitations related to the analyses. ART status was based on the recording of this information on VL test requisition forms—data that was missing on 17–20% of requisitions. However, we made conservative assumptions on ART status for requisitions with missing data. Further, we relied solely on VL tests as a proxy for care visits and not VL and CD4 tests as done in most studies (CD4 laboratory testing is not centralized in Ontario) [15]. In one cascade analysis, the percent of diagnosed PLWH who were in care was 4% absolute percentage points higher when both CD4 and/or VL tests were used as opposed to VL tests alone [21]. Information on HIV exposure category and race/ethnicity were missing for a large proportion of cohort participants, making it difficult to stratify indicators by these characteristics. Of note, our study team is currently evaluating multiple imputation approaches to address missing sociodemographic and ART data. Although our data were linked at the individual-level and longitudinal in nature, our analyses were mostly cross-sectional by year and based on a linear
conceptualization of the HIV cascade (as this is the traditional approach to measuring the cascade). Cross-sectional approaches fail to account for changes in a population over time and do not reflect the dynamic nature of HIV care [10,14]. Unlike many other cascade studies, we did not estimate engagement in “continuous care”, a cross-sectional measure typically defined as two care visits ≥3 months apart in a given year [16,17,21,51]. We were concerned about the potential impact of changing VL testing practices on the validity of this measure. For example, clinicians may recommend less frequent visits/measurement of VL for individuals who are healthy and durably suppressed, with the risk that such individuals could be misclassified as not engaged in continuous care if assessed by frequency of VL testing. A recent clinical cohort study found that 10% of participants not defined as being engaged in continuous care were virally suppressed, yet these individuals would be excluded from the numerator of subsequent cascade steps [58]. Future analyses of our cascade will explore longitudinal approaches informed by non-linear cascade frameworks and measure transitions in and out of different stages [59–62]. Finally, all our analyses were descriptive and future research will explore regression analyses to identify predictors of cascade engagement (pending strategies to address missing data).

There were also limitations related to the nature of our cohort. While we believe our cohort captures the vast majority of diagnosed PLWH in the province, a small number of individuals may have been missed due to the exclusion of non-nominal diagnoses and our indirect censorship for out-migration and death. However, we assume that the majority of non-nominally diagnosed individuals will present for HIV care and be included in the cohort as an individual with a VL test only (no linked diagnostic test). Of note, those diagnosed non-nominally who never connect to care are not included in our cohort, while non-nominally diagnosed individuals are less likely to be included in the newly diagnosed sample (as this sample excludes individuals with a VL test only). Further, as a result of indirectly censoring for death and out-migration (>2 years with no VL test and no VL test in later years), it is likely that some diagnosed individuals were inappropriately removed from our cohort. Indirect censorship is common in other studies of diagnosed PLWH but there is no standardized approach (LTFU rules range from 1.5 to 7 years with no healthcare use) [16,18,35]. Finally, our retrospective LTFU rule may have biased estimates in more current years, as those recently LTFU may not have had time to return to care and be retrospectively included as diagnosed PLWH. Linkage of our cohort to other administrative health care databases is planned in order to strengthen our data source.

In conclusion, our population-based assessment of HIV cascade indicators in Ontario demonstrates substantial improvement from 2000 to 2015. Our results also indicate room for further improvement, particularly among younger individuals. The results in this paper are the first to emerge from our newly created data source, the Ontario HIV Laboratory Cohort, and fill an important gap in our understanding of Ontario’s cascade. Notable limitations inherent to our data source include the exclusion of non-nominal diagnoses; missing ART, CD4 and sociodemographic information; and indirect censorship for out-migration and death. Future efforts will build upon these analyses by exploring non-linear cascade frameworks, stratifying estimates by region and priority population, and strengthening our data source via linkage to additional administrative health care databases.

Supporting information

S1 Table. Number of HIV-positive diagnostic tests by type of identifier (nominal and non-nominal), Ontario, 2000 to 2015.

(DOCX)
S2 Table. Temporal changes in sex and age distribution among Ontario HIV Laboratory Cohort participants, 2000 to 2015.

S3 Table. Comparison of characteristics for HIV-positive nominal diagnostic tests vs. non-nominal tests.

S1 Supporting Information. Underlying data for all figures in manuscript.

S2 Supporting Information. Flow diagram for creation of newly diagnosed sample from the Public Health Ontario HIV Laboratory datamart and annual number of newly diagnosed individuals from 2000 to 2015.

S3 Supporting Information. Cascade indicator estimates by sex and age (for indicators/figures not included in manuscript).

Acknowledgments

Disclaimer: The opinions, results and conclusions are those of the authors only. No endorsement by the Ontario HIV Treatment Network, Public Health Ontario or the Public Health Agency of Canada is intended or should be inferred.

We thank the individuals who make up the Ontario HIV Laboratory Cohort and the health care providers for completing the test requisitions and other surveillance forms. All data was provided to the Ontario HIV Epidemiology and Surveillance Initiative (OHESI) in de-identified aggregate format by the Public Health Ontario Laboratory with significant support from Public Health Ontario’s database team, in particular Jane Xiong and Ioana Belchita. OHESI is a collaboration involving the AIDS Bureau of the Ontario Ministry of Health and Long-Term Care (MOHLTC), Public Health Ontario (PHO), the Public Health Agency of Canada (PHAC), and the Ontario HIV Treatment Network (OHTN). Members of OHESI include Jean Bacon (OHTN), Beth Rachlis (OHTN), James Wilton (OHTN), Abigail Kroch (OHTN), Madison Giles (OHTN), Lucia Light (OHTN); Joanne Lush (MOHLTC), Ken English (MOHLTC); Doug Sider (PHO), Michelle Murti (PHO), Vanessa Allen (PHO), Tony Mazzulli (PHO), Mike Mendaglio (PHO), Alex Marchand-Austin (PHO), Juan Liu (PHO); and Ashleigh Sullivan (PHAC) and Chris Archibald (PHAC). OHESI is chaired by Dr. Abigail E. Kroch (akroch@ohtn.on.ca).

Author Contributions

Conceptualization: Ashleigh Sullivan, Doug Sider, Mark Gilbert.

Data curation: Juan Liu, Ashleigh Sullivan, Alex Marchand-Austin.

Formal analysis: Juan Liu.

Methodology: James Wilton, Juan Liu, Ashleigh Sullivan, Beth Rachlis, Alex Marchand-Austin, Lucia Light, Claudia Rank, Ann N. Burchell, Sandra Gardner, Mark Gilbert.

Project administration: Ashleigh Sullivan, Alex Marchand-Austin, Madison Giles.

Supervision: Doug Sider, Mark Gilbert, Abigail E. Kroch.
Visualization: James Wilton, Juan Liu, Mark Gilbert.

Writing – original draft: James Wilton, Mark Gilbert.

Writing – review & editing: James Wilton, Juan Liu, Ashleigh Sullivan, Beth Rachlis, Alex Marchand-Austin, Madison Giles, Lucia Light, Claudia Rank, Ann N. Burchell, Sandra Gardner, Doug Sider, Mark Gilbert, Abigail E. Kroch.

References

1. Hull MW, Wu Z, Montaner JSG. Optimizing the engagement of care cascade. Curr Opin HIV AIDS. 2012 Nov; 7(6):579–86. https://doi.org/10.1097/COH.0b013e3283590617 PMID: 23076123

2. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection. Clin Infect Dis. 2011 Mar 1; 52(6):793–800. https://doi.org/10.1093/cid/ciq243 PMID: 21367734

3. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, GrunD B, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015 Aug 27; 373(9):795–807. https://doi.org/10.1056/NEJMoa1506816 PMID: 26192873

4. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumaranayake L, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11; 365(6):493–505. https://doi.org/10.1056/NEJMoa1105243 PMID: 21767103

5. Montaner JSG, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006 Aug 5; 368(9534):531–6. https://doi.org/10.1016/S0140-6736(06)69162-9 PMID: 16890841

6. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013 Feb 22; 339(6122):966–71. https://doi.org/10.1126/science.1228160 PMID: 23430656

7. Hull M, Lange J, Montaner JSG. Treatment as prevention—where next? Curr HIV/AIDS Rep. 2014 Dec; 11(4):496–504. https://doi.org/10.1007/s11904-014-0237-5 PMID: 25384357

8. 90-90-90—An ambitious treatment target to help end the AIDS epidemic. UNAIDS. 2014. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf

9. Lourenço L, Hull M, Nosyk B, Montaner JSG, Lima VD. The need for standardisation of the HIV continuum of care. Lancet HIV. 2015 Jun; 2(6):e225–6. https://doi.org/10.1016/S2352-3018(15)00086-7 PMID: 26423191

10. Haber N, Pillay D, Porter K, Bärnighausen T. Constructing the cascade of HIV care: methods for measurement. Curr Opin HIV AIDS. 2016 Jan; 11(1):102–8. https://doi.org/10.1097/COH.0000000000000212 PMID: 26545266

11. McCarthy S, Hoffmann M, Ferguson L, Nunn A, Irvin R, Bangsberg D, et al. The HIV care cascade: models, measures and moving forward. J Int AIDS Soc. 2015; 18:19395. https://doi.org/10.7448/IAS.15.1.19395 PMID: 25735869

12. Miller WC, Lesko CR, Powers KA. The HIV care cascade: simple concept, complex realization. Sex Transm Dis. 2014 Jan; 41(1):1–2. PMID: 24326580

13. Hallett TB, Eaton JW. A side door into care cascade for HIV-infected patients? J Acquir Immune Defic Syndr 1999. 2013 Jul; 63 Suppl 2:S228–32.

14. Lesko CR, Sampson LA, Miller WC, Clymore J, Leone PA, Swygard H, et al. Measuring the HIV Care Continuum Using Public Health Surveillance Data in the United States. J Acquir Immune Defic Syndr 1999. 2015 Dec 15; 70(5):489–94.

15. Medland NA, McMahon JH, Chow EPF, Elliott JH, Hoy JF, Fairley CK. The HIV care cascade: a systematic review of data sources, methodology and comparability. J Int AIDS Soc. 2015; 18:20634. https://doi.org/10.7448/IAS.15.1.20634 PMID: 26626715

16. Torian LV, Xia Q, Wiewel EW. Retention in care and viral suppression among persons living with HIV/AIDS in New York City, 2006–2010. Am J Public Health. 2014 Sep; 104(9):e24–9. https://doi.org/10.2105/AJPH.2014.302080 PMID: 25033144

17. Dombrowski JC, Buskin SE, Bennett A, Thiede H, Golden MR. Use of multiple data sources and individual case investigation to refine surveillance-based estimates of the HIV care continuum. J Acquir Immune Defic Syndr 1999. 2014 Nov 1; 67(3):323–30.

18. Nosyk B, Montaner JSG, Colley G, Lima VD, Chan K, Heath K, et al. The cascade of HIV care in British Columbia, Canada, 1996–2011: a population-based retrospective cohort study. Lancet Infect Dis. 2014 Jan; 14(1):40–9. https://doi.org/10.1016/S1473-3099(13)70254-8 PMID: 24076277
19. Helleberg M, Häggblom A, Sönnerborg A, Obel N. HIV care in the Swedish-Danish HIV cohort 1995–2010, closing the gaps. PLoS One. 2013; 8(8):e72257. https://doi.org/10.1371/journal.pone.0072257 PMID: 23967292

20. Chkhartishvili N, Sharavadze L, Chokoshvili O, DeHovitz JA, del Rio C, Tsertsivadze T. The cascade of care in the Eastern European country of Georgia. HIV Med. 2015 Jan; 16(1):62–6. https://doi.org/10.1111/hiv.12172 PMID: 24919923

21. Gray KM, Cohen SM, Hu X, Li J, Morrin J, Hall HI. Jurisdiction level differences in HIV diagnosis, retention in care, and viral suppression in the United States. J Acquir Immune Defic Syndr. 1999. 2014 Feb 1; 65(2):129–32.

22. Horberg MA, Hurley LB, Klein DB, Towner WJ, Kadlecik P, Antoniakis D, et al. The HIV Care Cascade Measured Over Time and by Age, Sex, and Race in a Large National Integrated Care System. AIDS Patient Care STDs. 2015 Nov; 29(11):582–90. https://doi.org/10.1089/apc.2015.0139 PMID: 26505968

23. Backus L, Czarnogorski M, Yip G, Thomas BP, Torres M, Bell T, et al. HIV Care Continuum Applied to the US Department of Veterans Affairs: HIV Virologic Outcomes in an Integrated Health Care System. J Acquir Immune Defic Syndr 1999. 2015 Aug 1; 69(4):474–80.

24. Dombrowski JC, Kitahata MM, Van Rompaey SE, Crane HM, Mugavero MJ, Eron JJ, et al. High levels of antiretroviral use and viral suppression among persons in HIV care in the United States, 2010. J Acquir Immune Defic Syndr 1999. 2013 Jul 1; 63(3):299–306.

25. Althoff KN, Buchacz K, Hall HI, Zhang J, Hanna DB, Rebeiro P, et al. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med. 2012 Sep 4; 157(5):325–35. https://doi.org/10.7326/0003-4819-157-5-201209040-00005 PMID: 2294874

26. Campbell CNJ, Ambrosioni J, Miro JM, Esteve A, Casabona J, Narvaro G, et al. The continuum of HIV care in Catalonia. AIDS Care. 2015; 27(12):1449–54. https://doi.org/10.1080/09540121.2015.1109584 PMID: 26605781

27. Supervie V, Marty L, Lacombe J-M, Dray-Spira R, Costagliola D, group F-AC study. Looking Beyond the Cascade of Care to End the AIDS Epidemic: Estimation of the Time Interval From HIV Infection to Viral Suppression. J Acquir Immune Defic Syndr. 2016 Nov; 73(3):348–55. https://doi.org/10.1097/QAI.0000000000001120 PMID: 27351889

28. Van Beckhoven D, Florence E, Ruelle J, Deblonde J, Verhofstede C, Callens S, et al. Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants. BMC Infect Dis. 2015 Nov 3; 15:496. https://doi.org/10.1186/s12879-015-1230-3 PMID: 26530500

29. Kohler P, Schmidt AJ, Cavassini M, Furrer H, Calmy A, Battegay M, et al. The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. AIDS Lond Engl. 2015 Nov 28; 29(18):2509–15.

30. Bradley H, Hall HI, Wolitski RJ, Van Handel MM, Stone AE, LaFlam M, et al. Vital Signs: HIV diagnosis, care, and treatment among persons living with HIV—United States, 2011. MMWR Morb Mortal Wkly Rep. 2014 Nov 28; 63(47):1113–7. PMID: 25426654

31. Population by year, by province and territory (CANSIM table 051–0001). [cited 19 June 2018]. In: Statistics Canada [Internet]. http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo02a-eng.htm

32. HIV and AIDS in Canada: Surveillance Report to December 31, 2014. 2015 Dec 1 [cited 19 June 2018]. In: Public Health Agency of Canada [Internet]. https://www.canada.ca/en/public-health/services/publications/diseases-conditions/hiv-aids-canada-surveillance-report-december-31-2014.html

33. Bourgeois AC, Edmunds M, Awan A, Jonas L, Varsaneux O, Siu W. HIV in Canada—Surveillance Report, 2016. Can Commun Dis Rep Relève Mal Transm Au Can. 2017 Dec 7; 43(12):248–56.

34. New HIV diagnoses in Ontario: Preliminary report, 2016. Ontario HIV Epidemiology and Surveillance Initiative. 2017. http://www.ohesi.ca/documents/OHESI-New-HIV-Diagnoses-preliminary-updates.pdf

35. Antoniou T, Zagorski B, Bayouni AM, Loutfy MR, Strike C, Raboud J, et al. Trends in HIV prevalence, new HIV diagnoses, and mortality among adults with HIV who entered care in Ontario, 1996/1997 to 2009/2010: a population-based study. Open Med Peer Rev Indep Open-Access J. 2013; 7(4):e98–106.

36. HIV/AIDS Strategy to 2026: Focusing Our Efforts—Changing the Course of the Prevention, Engagement and Care Cascade in Ontario. Ontario Advisory Committee on HIV/AIDS. 2016. http://www.health.gov.on.ca/en/pro/programs/hiv/aids/docs/oach_strategy_2026.pdf

37. Burchell AN, Gardner S, Light L, Ellis BM, Antoniou T, Bacon J, et al. Implementation and Operational Research: Engagement in HIV Care Among Persons Enrolled in a Clinical HIV Cohort in Ontario, Canada, 2001–2011. J Acquir Immune Defic Syndr 1999. 2015 Sep 1; 70(1):e10–9.

38. Kendall CE, Younger J, Manuel DG, Hogg W, Glazier RH, Taljaard M. Health administrative data can be used to define a shared care typology for people with HIV. J Clin Epidemiol. 2015 Nov; 68(11):1301–11. https://doi.org/10.1016/j.jclinepi.2015.02.008 PMID: 25835491
39. Antoniou T, Zagorski B, Loufty MR, Strike C, Glazier RH. Validation of Case-Finding Algorithms Derived from Administrative Data for Identifying Adults Living with Human Immunodeficiency Virus Infection. Thiem U, editor. PLoS ONE. 2011 Jun 30; 6(6):e21748. https://doi.org/10.1371/journal.pone.0021748 PMID: 21738786

40. Medication Payment Assistance in Ontario. [cited 24 Nov 2018] In: University Health Network Toronto General Hospital [Internet]. https://hivclinic.ca/patient-information/medication-payment-assistance-in-ontario/

41. Yoong D, Bayoumi AM, Robinson L, Rachlis B, Antoniou T. Public prescription drug plan coverage for antiretrovirals and the potential cost to persons living with HIV in Canada: a descriptive study. Accepted CMAJ Open.

42. Toren KG, Buskin SE, Dombrowski JC, Cassels SL, Golden MR. Time From HIV Diagnosis to Viral Load Suppression: 2007–2013. Sex Transm Dis. 2016 Jan; 43(1):34–40. PMID: 26650994

43. Wiewel EW, Braunstein SL, Xia Q, Shepard CW, Torian LV. Monitoring outcomes for newly diagnosed and prevalent HIV cases using a care continuum created with New York city surveillance data. J Acquir Immune Defic Syndr 1999. 2015 Feb 1; 68(2):217–26.

44. National HIV/AIDS Strategy for the United States: Updated to 2020. 2015. https://files.hiv.gov/s3fs-public/nhas-update.pdf

45. Xia Q, Wiewel EW, Braunstein SL, Kersanske LS, Torian LV. Comparison of indicators measuring the proportion of human immunodeficiency virus-infected persons with a suppressed viral load. Ann Epidemiol. 2015 Apr; 25(4):226–30. https://doi.org/10.1016/j.annedem.2015.01.014 PMID: 25727312

46. Remis RS, Wu K, Sooliven D, Maregmen J, Allen M, Mazzulli T. Trends in HIV viral load testing in Ontario, 1996 to 2011. In: Canadian Association of HIV/AIDS Research (CAHR) Conference. Vancouver; 2013.

47. Hand DJ. Statistical challenges of administrative and transaction data. J R Stat Soc Ser A Stat Soc. 2018 Jun 1; 181(3):555–605.

48. van Walraven C, Austin P. Administrative database research has unique characteristics that can risk biased results. J Clin Epidemiol. 2012 Feb; 65(2):126–31. https://doi.org/10.1016/j.jclinepi.2011.08.002 PMID: 22075111

49. Rourke SB, Gardner S, Burchell AN, Raboud J, Rueda S, Bayoumi AM, et al. Cohort Profile: The Ontario HIV Treatment Network Cohort Study (OCS). Int J Epidemiol. 2013 Apr 1; 42(2):402–11. https://doi.org/10.1093/ije/dyr230 PMID: 22345312

50. Raboud J, Su D, Burchell AN, Gardner S, Walmsley S, Bayoumi AM, et al. Representativeness of an HIV cohort of the sites from which it is recruiting: results from the Ontario HIV Treatment Network (OHTN) cohort study. BMC Med Res Methodol. 2013 Dec; 13(1).

51. Rachlis B, Burchell AN, Gardner S, Light L, Raboud J, Antoniou T, et al. Social determinants of health and retention in HIV care in a clinical cohort in Ontario, Canada. AIDS Care. 2017 Jul; 29(7):828–37. https://doi.org/10.1080/09540121.2016.1271389 PMID: 28027668

52. Lourenço L, Colley G, Nosyk B, Shopin D, Montaner JSG, Lima VD, et al. High levels of heterogeneity in the HIV cascade of care across different population subgroups in British Columbia, Canada. PloS One. 2014; 9(12):e115277. https://doi.org/10.1371/journal.pone.0115277 PMID: 25451682

53. Fortenberry JD, Martinez J, Rudy BJ, Monte D, Adolescent Trials Network for HIV/AIDS Interventions. Linkage to care for HIV-positive adolescents: a multisite study of the adolescent medicine trials units of the adolescent trials network. J Adolesc Health Off Publ Soc Adolesc Med. 2012 Dec; 51(6):551–6.

54. Flicker S, Skinner H, Read S, Veinot T, McClelland A, Saulnier P, et al. Falling through the cracks of the big cities: who is meeting the needs of HIV-positive youth? Can J Public Health Rev Can Sante Publique. 2005 Aug; 96(4):308–12.

55. Tepper V, Zaner S, Ryscavage P. HIV healthcare transition outcomes among youth in North America and Europe: a review. J Int AIDS Soc. 2017 16; 20(Suppl 3):21490. https://doi.org/10.7448/IAS.20.4.21490 PMID: 28530041

56. Xia Q, Kersanske LS, Wiewel EW, Braunstein SL, Shepard CW, Torian LV. Proportions of patients with HIV retained in care and virally suppressed in New York City and the United States: higher than we thought. J Acquir Immune Defic Syndr 1999. 2015 Mar 1; 68(3):351–8.

57. Summary: Measuring Canada’s Progress on the 90-90-90 HIV Targets. Public Health Agency of Canada. 2016. http://healthycanadians.gc.ca/publications/diseases-conditions-maladies-affections/hiv-90-90-90-vih/index-eng.php

58. Yehia BR, Stephens-Shields AJ, Fleishman JA, Berry SA, Agwu AL, Metlay JP, et al. The HIV Care Continuum: Changes over Time in Retention in Care and Viral Suppression. PloS One. 2015; 10(6):e0129376. https://doi.org/10.1371/journal.pone.0129376 PMID: 26086089
59. Gillis J, Loutfy M, Bayoumi AM, Antoniou T, Burchell AN, Walmsley S, et al. A Multi-State Model Examining Patterns of Transitioning Among States of Engagement in Care in HIV-Positive Individuals Initiating Combination Antiretroviral Therapy. J Acquir Immune Defic Syndr 1999. 2016 Dec 15; 73(5):531–9.

60. Lesko CR, Edwards JK, Moore RD, Lau B. A longitudinal, HIV care continuum: 10-year restricted mean time in each care continuum stage after enrollment in care, by history of IDU. AIDS Lond Engl. 2016 Sep 10; 30(14):2227–34.

61. Colasanti J, Kelly J, Pennisi E, Hu Y-J, Root C, Hughes D, et al. Continuous Retention and Viral Suppression Provide Further Insights Into the HIV Care Continuum Compared to the Cross-sectional HIV Care Cascade. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016 Mar 1; 62(5):648–54.

62. Nosyk B, Loureço L, Min JE, Shopin D, Lima VD, Montaner JSG, et al. Characterizing retention in HAART as a recurrent event process: insights into “cascade churn”. AIDS Lond Engl. 2015 Aug 24; 29(13):1681–9.